Efficacy, Safety And Tolerability Study In Subjects With Parkinson's Disease
Efficacy, Safety And Tolerability Study In Subjects With Parkinson's Disease
The B7441003 study will assess PF-06412562 for motor benefit in Parkinson's disease subjects.
 Safety, tolerability and PK of PF-06412562 in Parkinson's disease subjects will also be
 evaluated.
Inclusion Criteria:

 -  Male or female subjects with a diagnosis of idiopathic Parkinson's disease.

 -  Daily L-dopa dose between 300 and 1200 mg.

 -  MBRS score >1.

 Exclusion Criteria:

 -  Surgical intervention for Parkinson's disease.

 -  History of troublesome dyskinesias.

 -  Any significant AXIS I psychiatric disease.